Posted by Michael Wonder on 20 Feb 2025
World’s first potential target therapy for diffuse gastric cancer granted fast track designation by the US FDA
20 February 2025 - Signet Therapeutics announced that the US FDA has granted fast track designation for SIGX1094, the world's first potential targeted therapy for diffuse gastric cancer.
In November 2024, SIGX1094 was also granted orphan drug designation from the FDA.
